Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 3:18 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Dengue Hemorrhagic Fever Clear all
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Study of Varying Injection Schedules of TDENV-PIV Vaccine With AS03B Adjuvant and Placebo in Healthy US Adults

NCT02421367
View directory record Official record
Conditions
Dengue
Interventions
TDENV-PIV with AS03B adjuvant. Placebo: 0.9% Sodium Chloride Solution.
Biological
Lead sponsor
U.S. Army Medical Research and Development Command
Federal
Eligibility
20 Years to 49 Years
Enrollment
140 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
2
States / cities
Baltimore, Maryland • Silver Spring, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 24, 2019 · Synced Jul 22, 2026, 3:18 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluating the Safety and Immune Response to Two Doses of a Dengue Virus Vaccine Administered 12 Months Apart

NCT01782300
View directory record Official record
Conditions
Dengue
Interventions
TV003 Vaccine, Placebo Vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
2
States / cities
Baltimore, Maryland • Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Jun 13, 2017 · Synced Jul 22, 2026, 3:18 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety of and Immune Response to a Dengue Virus Vaccine (rDEN4delta30-200,201) in Healthy Adults

NCT00270699
View directory record Official record
Conditions
Dengue Fever
Interventions
rDEN4delta30-200,201, Placebo
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2009
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 2, 2013 · Synced Jul 22, 2026, 3:18 AM EDT
Enrolling by invitation No phase listed Observational

Xpert® Tropical Fever Test on GeneXpert® Edge X System

NCT07520279
View directory record Official record
Conditions
Malaria Fever, Zika, Dengue Fever, Leptospirosis, Chikungunya Virus Infection
Interventions
Xpert Tropical Fever test
Diagnostic Test
Lead sponsor
Cepheid
Industry
Eligibility
14 Years and older
Enrollment
2,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Apr 8, 2026 · Synced Jul 22, 2026, 3:18 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Immunogenicity and Safety of Three Formulations of Dengue Vaccines in Healthy Adults Aged 18 to 45 Years in the US

NCT00617344
View directory record Official record
Conditions
Dengue Fever, Dengue Hemorrhagic Fever, Dengue Virus
Interventions
Tetravalent CYD Dengue Vaccine , 5555 formulation, Tetravalent CYD Dengue Vaccine , 5553 formulation, Tetravalent CYD Dengue Vaccine, 4444 formulation
Biological
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 45 Years
Enrollment
260 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
5
States / cities
Hoover, Alabama • San Diego, California • Vallejo, California + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2019 · Synced Jul 22, 2026, 3:18 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety of and Immune Response to DEN4 Vaccine Component Candidate for Dengue Virus

NCT00919178
View directory record Official record
Conditions
Dengue Shock Syndrome, Dengue Hemorrhagic Fever
Interventions
DEN4 Vaccine Candidate, DEN4 Vaccine Placebo
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
2
States / cities
Baltimore, Maryland • Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Jan 2, 2013 · Synced Jul 22, 2026, 3:18 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Determine the Safety of AV-1, an Antibody Being Developed for Treatment of Dengue, in Healthy Volunteers

NCT04273217
View directory record Official record
Conditions
Healthy Volunteers
Interventions
AV-1, Placebo
Drug
Lead sponsor
AbViro LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Oct 30, 2022 · Synced Jul 22, 2026, 3:18 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety of and Immune Response to a Dengue Virus Vaccine (rDEN3delta30/31-7164) in Healthy Adults

NCT00831012
View directory record Official record
Conditions
Dengue Fever
Interventions
rDEN3delta30/31-7164
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2009
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 14, 2013 · Synced Jul 22, 2026, 3:18 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

Safety and Pharmacokinetics of UV-4B Solution Administered Orally as Multiple Ascending Doses to Healthy Subjects

NCT02696291
View directory record Official record
Conditions
Viral Infection
Interventions
UV-4B 30 mg oral solution, UV-4B 75 mg oral solution, UV-4B 150 mg oral solution, UV-4B X mg (dose to be determined) oral solution, UV-4B Y mg (dose to be determined) oral solution, Placebo
Drug
Lead sponsor
Emergent BioSolutions
Industry
Eligibility
18 Years to 45 Years
Enrollment
7 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
2
States / cities
Dallas, Texas • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Mar 17, 2024 · Synced Jul 22, 2026, 3:18 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety of and Immune Response to Two Different Dengue Virus Vaccines in Individuals Previously Immunized Against Dengue Virus

NCT00458120
View directory record Official record
Conditions
Dengue Hemorrhagic Fever
Interventions
rDEN1delta30, rDEN2/4delta30(ME), Placebo to rDEN1delta30 or rDEN2/4delta30(ME)
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 13, 2010 · Synced Jul 22, 2026, 3:18 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Procleix® Dengue Virus Assay Testing of Individual Donor Samples From Puerto Rican and US Blood Donors - CTS

NCT01702272
View directory record Official record
Conditions
Dengue
Interventions
Procleix Dengue Virus Assay
Device
Lead sponsor
Gen-Probe, Incorporated
Industry
Eligibility
Not listed
Enrollment
150,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
St. Petersburg, Florida
Source: ClinicalTrials.gov public record
Updated Sep 14, 2014 · Synced Jul 22, 2026, 3:18 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Tetravalent Chimeric Dengue Vaccine Trial

NCT01110551
View directory record Official record
Conditions
Dengue
Interventions
Placebo (SC), Placebo (ID), Modified Live Tetravalent Chimeric Dengue Vaccine (SC), Modified Live Tetravalent Chimeric Dengue Vaccine (ID)
Drug · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 3, 2013 · Synced Jul 22, 2026, 3:18 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety of and Immune Response to a Dengue Virus Vaccine (rDEN4delta30-4995) in Healthy Adults

NCT00322946
View directory record Official record
Conditions
Dengue
Interventions
rDEN4delta30-4995, Placebo
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2007
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 6, 2009 · Synced Jul 22, 2026, 3:18 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Study of AT-752 in Healthy Subjects in a Dengue Human Challenge Model

NCT05366439
View directory record Official record
Conditions
Dengue
Interventions
AT-752, Placebo Comparator
Drug
Lead sponsor
Atea Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Syracuse, New York
Source: ClinicalTrials.gov public record
Updated Apr 20, 2023 · Synced Jul 22, 2026, 3:18 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

An Evaluation of Repeated Oral Doses of JNJ-64281802 Against DENV-3 Challenge

NCT05048875
View directory record Official record
Conditions
Dengue
Interventions
Cohort 1 - Group 1 JNJ High Dose, Cohort 1 - Group 2 JNJ Medium Dose, Cohort 1 - Group 2 JNJ Low Dose, Cohort 1 - Group 1/2 Placebo
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 55 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
2
States / cities
Baltimore, Maryland • Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Apr 23, 2025 · Synced Jul 22, 2026, 3:18 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Impact of SC vs IM Administration of DENVax (TDV) on Safety and Immunogenicity

NCT01728792
View directory record Official record
Conditions
Dengue Fever
Interventions
TDV
Biological
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 45 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Syracuse, New York
Source: ClinicalTrials.gov public record
Updated Jul 17, 2019 · Synced Jul 22, 2026, 3:18 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

ADVP005; Dengue CVD 12000 - Dengue-1-Virus Live Virus Human Challenge (DENV-1-LVHC)

NCT04786457
View directory record Official record
Conditions
Dengue
Interventions
Dengue 1 Live Virus Human Challenge (DENV-1-LVHC)
Biological
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 50 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 26, 2025 · Synced Jul 22, 2026, 3:18 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Trial of a Walter Reed Army Institute of Research (WRAIR) Live Attenuated Virus Tetravalent Dengue Vaccine in Healthy US Adults

NCT00239577
View directory record Official record
Conditions
Dengue
Interventions
Live attenuated tetravalent dengue vaccine, Placebo
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 45 Years
Enrollment
86 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
1
States / cities
Silver Spring, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 18, 2019 · Synced Jul 22, 2026, 3:18 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Procleix® Dengue Virus Assay Testing of Individual Donor Samples From Puerto Rican Blood Donors - American Red Cross

NCT01656174
View directory record Official record
Conditions
Dengue
Interventions
Procleix Dengue Virus Assay
Device
Lead sponsor
Gen-Probe, Incorporated
Industry
Eligibility
Not listed
Enrollment
35,035 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2015
U.S. locations
2
States / cities
Tempe, Arizona • Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 19, 2015 · Synced Jul 22, 2026, 3:18 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluating the Safety and Effectiveness of a Dengue Virus Vaccine in Healthy Adults

NCT02021968
View directory record Official record
Conditions
Dengue
Interventions
TetraVax-DV-TV003, rDEN2∆30-7169, Placebo
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
2
States / cities
Baltimore, Maryland • Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Dec 14, 2015 · Synced Jul 22, 2026, 3:18 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of the Safety and the Ability of a DNA Vaccine to Protect Against Dengue Disease

NCT01502358
View directory record Official record
Conditions
Dengue Disease, Dengue Fever
Interventions
Tetravalent Dengue Vaccine (TVDV), Tetravalent Dengue Vaccine (TVDV) with Vaxfectin® (low-dose), Tetravalent Dengue Vaccine TVDV with Vaxfectin® (High Dose)
Biological
Lead sponsor
U.S. Army Medical Research and Development Command
Federal
Eligibility
18 Years to 50 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
1
States / cities
Silver Spring, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 3, 2016 · Synced Jul 22, 2026, 3:18 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety of and Immune Response to a Dengue Virus Vaccine (rDEN1delta30) in Healthy Adults

NCT00089908
View directory record Official record
Conditions
Dengue Fever
Interventions
rDEN1delta30, Placebo
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2005
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 17, 2008 · Synced Jul 22, 2026, 3:18 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluating the Safety and Protective Efficacy of a Single Dose of the Live Attenuated Tetravalent Dengue Vaccine TV005 to Protect Against Infection With rDEN3Δ30

NCT02873260
View directory record Official record
Conditions
Dengue
Interventions
TetraVax-DV-TV005, rDEN3Δ30, Placebo
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
2
States / cities
Baltimore, Maryland • Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Mar 7, 2018 · Synced Jul 22, 2026, 3:18 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluating the Safety and Immune Response to Two Admixtures of a Tetravalent Dengue Virus Vaccine

NCT01436422
View directory record Official record
Conditions
Dengue
Interventions
TetraVax-DV Vaccine - Admixture TV003, TetraVax-DV Vaccine - Admixture TV005, Placebo
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
112 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2014
U.S. locations
3
States / cities
Baltimore, Maryland • Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Aug 19, 2015 · Synced Jul 22, 2026, 3:18 AM EDT